**Title**: **Tobacco chewing, Alcohol consumption, reuse of cloth sanitary pads is significant risk factors for High Risk HPV infection and PAP positivity among Rural Women of Kamrup District, North-East India**

**Running Title:** CareHPV and PAP testing in rural women, North –East India

**Authors**: Pallavi Sarma[1], Debabrata Barmon[2#], Avdhesh Kumar Rai[3#], Amal Chandra Kataki[4], Anupam Sarma[5], Lopamudra Kakoti[6], Debanjana Barman[7], Manoj Kalita[8]

**Affiliations**:

1. Pallavi Sarma , MSc, Junior Research Fellow, DBT Centre for Molecular Biology & Cancer Research, Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA  E-mail- sarma931pallavi@gmail.com  Mobile : +91 8876415907

2. Dr Debabrata Barmon, MD , Professor & Head, Department of Gynaecologic Oncology, Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA   E-mail:drdbarmon@gmail.com   Mobile:+91 9101219476

3. Dr Avdhesh Kumar Rai, PhD , Assistant Research Officer (Scientific Officer-D), DBT Centre for Molecular Biology & Cancer Research, Dr B. Borooah Cancer Institute,  A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA  E-mail: dravdheshkumarrai@gmail.com  Mobile: +91 9101491648   ORCID ID: 0000-0002-8699-8400

4. Amal Chandra Kataki ,MD, Director , Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA  Email:dramalchkataki@yahoo.com  Mob:+91 9864096972

5.  Anupam Sarma ,MD, Professor & Head, Department of OncoPathology, Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA  Email:dranupamsarma@gmail.com  Mob: +91 9864016791

6.  Lopamudra Kakoti , MD, Assistant Professor, Department of OncoPathology, Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA Email:lopamudrakakoti@gmail.com   Mob:+91 7086082249

7.  Debanjana Barman ,MD, Medical Officer,  Dr B. Borooah Cancer Institute, Population Based Cancer Registry, Guwahati-781016, Assam, INDIA , Email:dr.debanjanabarman@gmail.com  Mob:7002116505

8. Manoj Kalita ,MSc. ,Biostatistician,  Dr B. Borooah Cancer Institute, Population Based Cancer Registry, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA Email : manojkalita5354@gmail.com  Mobile : 9365508863

# Corresponding Author(s): **Dr Avdhesh Kumar Rai**, Ph.D., Assistant Research Officer (Scientific Officer-D), DBT Centre for Molecular Biology & Cancer Research, Dr B. Borooah Cancer Institute, Gopinath Nagar, Guwahati-781016, Assam, INDIA

Phone No. +91 9101491648; Fax: +91 361 2472636; **E-mail:**dravdheshkumarrai@gmail.com

**ORCID ID**: 0000-0002-8699-8400

**Dr Debabrata Barmon**, M.D., Professor & Head, Department of Gynaecologic Oncology, Dr B. Borooah Cancer Institute, A. K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA    E-mail:drdbarmon@gmail.com   Mobile:+91 9101219476

## ABSTRACT

### BACKGROUND

To screen asymptomatic rural women for High Risk HPV DNA by CareHPV ® test and cytological screening by Papanicolaou (PAP) test.

### METHOD

A total of Four hundred eighty (n=480) sexually active, non pregnant women in the age group of 20- 70 years were included in this study. Two cervical scrap samples were collected from enrolled eligible women, one scrap sample was used for HPV testing (CareHPV®) and second for Papanicolaou (PAP) testing. Statistical analysis for testing outcome with demographic characteristics was analyzed using 95% confidence intervals (95% CI) for different variables. P-values<.05 values were considered statistically significant.

### RESULTS

Among tobacco chewing group of women compared to non-tobacco chewing women positivity rate for high risk HPV (p-0.001) and PAP test (p-0.007) was found to be statistically significant. Alcoholic beverage consuming women group has shown 28 times higher risk of high risk HPV infection (OR-28.3; p-0.0001) compared to non-alcoholic women. Irregular menstruation was found to be significant risk factor for PAP positivity (OR-14.33; p-0.001). High risk HPV infection (p-0.02) and PAP positivity (p-0.0001) was significantly higher in cloth sanitary pad user compared to commercial sanitary pad user. We also found that >3 numbers of childbirth as a significant risk factor for hr-HPV infection (p-0.0122).

### CONCLUSION

We conclude that among rural women of Kamrup, North-East India alcohol consumption, tobacco chewing, cloth sanitary pad reuse , >3 child birth were significantly associated with increased risk of hr-HPV infection and PAP positivity.

**Key Words**: careHPV, PAP, high risk HPV, rural women, North-East India

# INTRODUCTION

 Cervical cancer is a significant health challenge throughout India and the world. Globally in the year 2020, 604127 new cervical cancer cases and 341831 deaths were reported. Further in that year 123 907 new cases and 77 348 deaths were reported for India[1].

With early diagnosis and vaccination cervical cancer can be prevented effectively. Cervical cancer mortality can be reduced by up to 80% with high-quality screening by Papanicolaou tests (PAP)[2].

There have been emergences of different cervical screening techniques such as Papanicolaou (PAP) test, human Papillomavirus (HPV) DNA tests and visual inspection with acetic acid (VIA) which are feasible in low resource settings. Various report suggest an association of HPV infection with positive or negative PAP test results[3]. The PAP cytology test has been implemented as an easy and cost effective primary screening method in various developed countries, which has reduced cervical cancer cases by 50–70%[4].

Limitation in implementation of effective screening programs across nation remains a major hurdle in low- and middle-income countries (LMICs)[5]. Major implementation challenges for screening programs in LMICs is due to their procedural complexity, need for highly trained technicians & pathologists for reading the samples, need for good quality control and average sensitivity of the test even under optimal conditions[6]. But sometimes PAP smear test have false negative results. also and require skilled people for diagnoses  as the sensitivity of PAP smears to detect cancer or pre-cancerous is equal to 53% , which leads up to a 50% increase in false negative results[7].

Combining early detection of high-risk HPV in *Cervical* intraepithelial neoplasia (CIN) lesions and HPV vaccination may  provide higher efficacy in detection of treatable stage CIN lesions and prevention of HPV infection in general women population. Screening programs

for cervical cancer prevention can be able to achieve best deliverables if they adopt an age appropriate screening strategy for better follow up compliance from participant women of different geographical, ethnic and cultural background[8].

US-FDA has approved Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD, USA) as a primary screening techniques for high risk HPV DNA detection and it was widely used in many studies across the world. The CareHPV ( Qiagen, Gaithersburg, MD) Test utilizes the same Hybrid Capture® 2 technology developed by QIAGEN's digene ® HC2 High-Risk HPV DNA Test (HC2 Test) but is more simplified and can be conducted by technicians for use in low resource settings such as rural areas without electricity and running tap water. In rural areas where robust PAP test is not possible care HPV test is most preferred tool for cervical screening[9].

The care HPV test has been found to have more than 88 % sensitivity with regard to advanced CIN lesions in detection in conjunction with hr HPV[10]. On the basis of the real world setting data from various studies of care HPV test has provided good consensus data. Therefore World Health Organization (WHO) and other public health agencies are recommending care HPV testing as primary screening tool along with visual inspection by acetic acid (VIA) in resourced constrained developing countries.

 In North-East India, cervical cancer incidence rate range from 4.9 to 30.2 per 1,000,000 particularly Papumpare district (30.2), Aizawl district (28.0), Mizoram state (23.1) and Pasighat (22.5) have considerably higher rates than the rest of India[11]. The likelihood any type of cancer development over a lifetime (0-74 years) is highest among North East Indian females of Mizoram state (1 in 5 females) followed by Kamrup urban district (1 in 6 females) and Meghalaya (1 in 9 females)[12].

This study was carried out to screen rural asymptomatic  women  Kamrup urban district, Assam, India for *Cervical* intraepithelial neoplasia (CINs) and  High Risk HPV by CareHPV ® test  and Papanicolaou (PAP) test  .

**MATERIALS AND METHOD**

Study participant were enrolled since April 2017 – Dec 2020 from awareness cum screening camps organised in rural areas of Kamrup district, Assam, India. A total of Four hundred eighty (n=480) sexually active, non-pregnant women in the age group of   20- 70 years were included in this study. Women with history of CIN, pelvic radiation, hysterectomy or any co-morbidity were excluded from the study. A written consent was obtained from all eligible women participating in the study. Information such as socio-demographic characteristics (age, educational level, marital status, occupation), sexual practices (age of first sexual intercourse), reproductive health (number of pregnancies, children, place of child birth, use of contraceptives methods), general health (smoking habits, alcohol habits, tobacco habits) were collected in proforma questionnaire through personal interview. The Institutional Ethics Committee of Dr Bhubaneswar Borooah Cancer Institute (No. BBCI/IEC/26/06) has approved this study.

 **Sample collection for CareHPV® Test**

The enrolled eligible women were screened for high risk HPV DNA by CareHPV® test. Two cervical scrap samples were collected from each study participant, one for HPV testing (CareHPV®) and second for PAP testing. The samples were properly labelled and stored at 15 to 30 °c for 14 days or at 2 -8 °C for long time.

A 1-1.5cm of careBrush® was inserted gently into the cervix and rotates the care brush 3 full turns in a clockwise direction to collect the scrap. The cervical scrap samples were collected in care HPV Collection medium.

The samples were tested by care HPV platform (Qiagen) according to the manufacturer's instructions. This HPV test is an in vitro nucleic acid hybridization assay using microplate chemiluminescent detection as well as a rapid batch test for the qualitative detection of 14 High Risk (HR) HPV subtypes .CareHPV measures the ratio between the relative light unit and a cut-off and displays positive or negative results of the test without specifying the luminescent signal intensity. Samples were considered positive for hr-HPV when this ratio is ≥1. In careHPV more than 90 specimens can be processed and tested for hr-HPV within 2.5 hours.

**Papanicolaou (PAP) Test**

Additionally, a cervical specimen was collected using brush from both the ecto- and endocervix and rolled onto a glass slide, which was fixed in ethanol for cytological analysis using the Papanicolaou test (PAP test).The Bethesda system for reporting  for cytology was used for cytological results :  NILM (negative for intraepithelial lesions and malignancy) which includes inflammatory changes and atrophic changes; ASCUS ( Atypical squamous cells of undetermined significance); LSIL (low-grade squamous intraepithelial lesions); and HSIL (high grade squamous intraepithelial lesions).Women identified with atypical squamous cells of undetermined significance (ASCUS), low-grade intraepithelial lesion (LSIL) and high-grade intraepithelial lesions (HSIL) on PAP test were considered as positive. A woman who screened positive for any of the above tests was advised to undergo colposcopy and a biopsy guided by colposcopy, if necessary. The gold standard was histopathology.

**Hybrid capture2 (HC2) Assay for validation of CareHPV Test outcome**

The HC2 assay uses in vitro nucleic acid hybridization for qualitative detection of 13 types of high-risk HPV by signal amplification rather than DNA amplification. Target DNA in specimens was hybridized to a specific HPV RNA probe and RNA–DNA hybrids were captured and detected in microplate chemiluminescence by Luminometer. Light signals were measured as relative light units (RLUs) with light intensity indicating the presence or absence of target DNA in the tested specimen. RLU measurements equal to or higher than the cutoff (CO) value (RLU/CO≥1), indicated the presence of HPV DNA in the sample. RLU/ CO<1 indicated the absence of specific HPV DNA or HPV DNA below the detection limit. When RLU is equal to CO it confers the presence of approximately 5,000 virus copies in the specimen. The high-risk HPV quality control was 5 pg/ml cloned HPV 16 and carrier DNA. The high-risk HPV calibrator was 1 pg/ml cloned HPV 16 and carrier DNA. The negative calibrator was carrier DNA. Two confirmed cases of cervical cancer with High risk HPV positivity were also used as control samples. All the CareHPV tested samples (negative and positive) have been validated by HybridCapture2 test and all samples with positivity in both the test run were scored as positive. CareHPV and HC2 test concordance was 100%. The test reports were generated as per the format of the Hybrid Capture™ software ver. 2.0

**Statistical Analysis**

hr-HPV prevalence was shown according to different demographic characteristics and Chi-square tests were used to compare the differences of hr-HPV prevalence between different groups. P<.05 was considered as statistically significant. Bivariate logistic regression was conducted to calculate the odds ratios (OR) and 95% confidence intervals (CI) for the association between various factors and hr-HPV infection. SPSS ver21 was used for all statistical analyses(18%).

**RESULTS**

**Study Participant Characteristics**

A total of 500 women participants had participated in this study and 20 women were excluded due to unsatisfactory cytology and missing data Therefore effective participant were 480. The age group of the participating women ranged from 16-60 years and age distribution of the study population is 16 women were ≤20 years ,70 women were 21- 30 years and 395 women were >30 years. In this study we analysed the association of high risk HPV(hr-HPV) infection and PAP positivity with respect to demographic and behavioural characteristic like age, education level, tobacco habit , alcohol habit, age of marriage, age at first pregnancy, use of contraceptives, use of sanitary pads, and having urinary tract infection. In this study of all participant women were married. High proportion of participants had completed their high school education( 51%) and 11.7 % were college graduate but 29.4% participants were found illiterate and 8.1% of participants received primary education (TableI).

**Cytological and careHPV Test Outcome**

PAP smears of 7% (34/480) women showed cytological abnormalities. 2.7 % (13/480) participants had positive results for ASCUS, 3.75 % (18/480) had LSIL and 0.62% (3/480) had HSIL .High Risk HPV (hr-HPV) DNA was detected by CareHPV in 3.33% (16 / 480) of samples analysed (Table2). Women who have both positive cytology and positive hr- HPV DNA outcome were 1.4% (7/480) (Table II).

**Association of hr-HPV infection with Habit Factors**

A significant difference in high risk HPV infection was observed between the women who chew tobacco and those who do not (p -0.001). Tobacco chewers have 5.4 times the risk of

high risk HPV infection as non-tobacco chewers. The association between tobacco chewers and PAP positivity was also significant (p-0.007).Alcoholic beverage consuming women group has also shown 28 times significantly higher risk of high risk HPV infection (p-0.0001). Women having the habit of chewing betel leaf with areca nut with or without tobacco have not shown any statistical significance for infection with hr-HPV (Table I).

**Association of hr-HPV infection with Reproductive Health Factors**

In this study, 5% of the participants had no children whereas 61.7 % had 1-2 children and 33.3 % had ≥3 children (OR-0.2703 CI-95%- 0.122; p-0.0122). In our study there was no statistically significant association between the percentages of women who did not use contraceptives (3.6%) and those who did use contraceptives (2.7%). Irregular menstruation is found to as a significant risk factor for PAP infection(OR 14.33 CI- 6.11to 33.59 p-0.001). It was also found that 63.5% participants used sanitary pads (commercial) and 32.2% did not use. hr- HPV infection and PAP infection was significantly higher in women who did not use any sanitary pads compared to regular user of sanitary pads (p -0.02 hrHPV, p-0.0001 PAP). Participants and 2.5% of their marital partner have urinary tract infection. PAP positivity was found to be correlated with urinary tract infection of husband, but not with care HPV (Table II , Table III).

**Validation of care HPV results by Hybrid capture** :

All 16 samples which were found to be positive by careHPV test were further validated by Hybrid capture2 test. All samples were scored positive with RLU/CO value >1. The cut off (CO) value is 2275 (Table IV).

**DISCUSSION**

Our study aim to investigate prevalence of hr-HPV infection and PAP positivity in rural women of Kamrup district, North-East India and their association with epidemiological factors.

The prevalence of high Risk HPV infection among women in rural Kamrup district is 3.1% which is similar to that of Northern India (rural Uttar Pradesh) where the positivity rate for vaginal HPV, cervical HPV, VIA, and Papanicolaou testing were 2.4%, 2.9%, 5.5%, and 2.8%, respectively. From Southern India (Hyderabad) the positivity rate for vaginal HPV, cervical HPV, VIA, and Papanicolaou testing were 5.9%, 6.3%, 9.3%, and 3.5%, respectively[13]. In rural areas of West Bengal among general women population, the combined prevalence of HPV 16 and HPV 18 was reported to be 7.5 and 9.6%[14]. Our hr-HPV infection frequency by care HPV from cervical specimen among rural women of Assam was similar to North Indian state but it is lower compared southern and eastern Indian state. Prevalence of hr-HPV (HPV-16,-18,-31,-45,-58,-59) in invasive cervical cancer cases of Kamrup district was found 98% whereas in other states of India like Odisha has 94.28% [15] and Delhi NCR has 68.6%[16]. These differences in hr-HPV positivity frequency may be attributed to the choice method of detection for HPV, ethnic and cultural variations.

A prevalence of 2.7 % for positive ASCUS observed in our study which is less than that observed in another study conducted in Delhi[17]. Different studies conducted across the world have also found ASCUS positivity varying from 0.6 to 4.5 %[18]. A study from Brazil reported more than fivefold difference in ASCUS prevalence[19]. In rural China, careHPV test sensitivity and specificity to detect CIN2+ lesion was found to be 72.5% and 86.0% respectively[20]. Cytology based analysis are prone to inter-individual observation variations related to duration of experience of the technologist, pathologist in PAP smear cytology.

We observed that tobacco chewers are at 5.4 times more risk of hr HPV infection and PAP positivity than non-chewers (CI 95%- 1.726-17.125; p - 0.001 hr HPV and CI 95%- 1.261 to 4.908; p - 0.007 PAP). It has been shown that women who smoke have a significantly increased risk of cervical cancer compared with non-smokers, even when adjusting for HPV infections[21]. Tobacco chewing and smoking is directly associated with up to 98% cases of hr-HPV infection[16].

The concentration and duration of exposure to nicotine may alter the antigen signaling pathways of immune cells and their responses for bacterial/ viral infection[22].Association of smoking with increased risk for hr-HPV infection may be due to residual confounding from HPV or other sexually transmitted pathogens[20]. Around 50% Risk of Cervical cancer was reduced among those who ceased smoking for 10 years compared to those who remain smoker[19].

Our investigation found significantly higher risk of hr HPV infection among alcoholic women (CI 95%-6.321-126.733;p-0.0001). Alcohol consumption increases the risk of cervical hr-HPV persistence and cervical intraepithelial neoplasia (CIN)[22]. Furthermore, alcohol drinkers showed a higher risk of cervical intraepithelial neoplasia (CIN) 1 compared with abstainers. High drinking frequency and quantity from alcohol aggravated the issue [23].Women with light alcohol intake (<5 g/day) had a 22% lower endometrial cancer risk[24] Acetaldehyde associated with alcohol metabolism is considered as carcinogenic[25]. Indigenous ethnic communities in North-East India prepare local alcoholic beverages. Most of them are unrefined, unhygienic and have percentage to raw alcoholic constituents which may have detrimental effect on women health.

Prevalence of hr- HPV was found higher in non-user of contraceptives but the association was not statistically significant. Some studies observed that use of condoms is not totally

reliable to prevent the HPV infection since condom do not block the contact with pubic skin and papilloma virus lives in skin covering pubic area as well as the cells lining the vagina and cervix in women and anus in both sexes[26]. Appleby et al. analyzed 24 studies worldwide and concluded that the relative risk of cervical cancer is increased in those who use hormonal contraception[27].

We found in our study that hr- HPV infection and PAP positivity was significantly higher in women who did not use any sanitary pads compared to regular user of sanitary pads (CI 95% - 1.346-10.59;p-0.007 hr HPV CI 95% - 3.601 to 15.33; p-0.0001 PAP). Use of homemade sanitary napkins increases the risk of hr HPV infection. Most of the women use cloths as sanitary napkins during menstruation and reuse it after washing which increase the infection rate[26]. Our finding was also supported by a study conducted in Maharashtra by collecting menstrual cloth to detect the presence of HPV and they found that the use of pads made from reused cloth increases the risk of developing dysplasia and cervical cancer[27].

In our study, menstrual irregularity (CI 95%6.111 to 33.59 p- 0.001)and urinary tract infection of spouse(CI 95%1.989 to 8.328 p- 0.001) are found significant risk factors for PAP positivity. Irregular menstruation increases the risk of hr-HPV infection and PAP positivity .Urinary tract infection of spouse is also found as a risk factor for PAP positivity. It was reported that presence of hr HPV and PAP positivity was detected in urinary tract of men with urethritis. Urethritis itself might increase the risk of HPV infection in the urinary tract as micro-injury is necessary for HPV to access the basal cells of the epithelium[28].

We found that more than 3 numbers of childbirth as significant risk factor for hr-HPV infection. Pregnancy induced cervical changes include increase in number of squamous metaplastic cells in transformation zones, makes women more susceptible to hr-HPV infection and in future their progression towards CIN and invasive cervical cancer[29]. It is

suggested that more number of child birth due to repeated hormonal changes and labour related trauma may increases the risk of hr-HPV infection in women[26]. It was reported in a Brazilian study that unscreened/ under screened women who were reluctant or unable to participate in clinic-based cervical screening, has better compliance to screening programme when provided with self-collection for HPV testing modality. It is suggested that health education and one-to-one counselling to asymptomatic women regarding benefits of HPV testing may be an implementable strategy in rural settings of India for Self sampling based hr-HPV DNA testing[30].

Awareness for avoiding risk factors, early recognition of signs and symptoms of precancerous cervical lesions and cervical cancer, genital hygiene and screening for early detection followed by treatment of precancerous lesions in asymptomatic women can reduce the incidence rate and mortality from cervical cancer in rural women of North-East India. Self-sampling for careHPV test based screening strategy in rural areas of North-East India may increase the participation and wider coverage of women population to achieve effective cervical cancer prevention. Towards successful implementation of mass HPV vaccination for prevention of cervical cancer in India, there will be requirement of extensive hr-HPV infection status data in various ethnic and geographic locations.

**CONCLUSION**

We conclude from our present study that alcohol consumption, tobacco chewing, reuse of cloth sanitary pad, more than 3 childbirth were significant risk factors associated with increased risk of hr-HPV infection among the rural women of Kamrup district of Assam, North-East India. Further studies will be required to validate our current observation in large cohort of women from different part of Assam and North-East India.

## ACKNOWLEDGEMENT

The authors are grateful to the Department of Health Research (DHR), Government of India, New Delhi, India, for providing research grant (No.V.25011/465/2016-GIA/HR) for this study. The authors express their gratitude to all women participant of this study.

## CONFLICT OF INTEREST STATEMENT

All authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

## AVAILABILITY OF DATA

All authors declare that data of the research study are provided in tables and figures. There is no dataset/ software created as part of this study.

## ETHICS APPROVAL

Study was conducted in compliance of the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The study was approved by the institutional ethics committee of Dr. Bhubaneswar Borooah Cancer Institute (BBCI) [No. BBCI/IEC/26/06]. The Institutional ethics committee of Dr. Bhubaneswar Borooah Cancer Institute is registered (ECR/1040/Inst/AS/2018/RR-22) with Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India.

## CONSENT FOR PUBLICATION

All authors have read and approved the manuscript for submission and publication.

**REFERENCES**

1. Sung H, Ferlay J, Siegel R L, Laversanne M et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2021; 71:209–249.

2. Zhang, J., Zhao, Y., Dai, Y., Dang, L., Ma, L., Yang, C. et al. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label Randomized Clinical Trial. *JAMA oncology* 2021 ;7(2) : 263–270.

3. Katki, Hormuzd A., et al. Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organization. The Lancet Oncology 2011 ;12.7 : 663.

4. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.

5. Dykens J A, Smith J S, Demment M et al. Evaluating the implementation of cervical cancer screening programs in low-resource settings globally: a systematized review. Cancer Causes Control 2020; 31: 417–429.

6. Lynette Denny, Louise Kuhn, Chih-Chi Hu, Wei-Yann Tsai, Thomas C. Wright .Human Papillomavirus–Based Cervical Cancer Prevention: Long-term Results of a Randomized Screening Trial. *JNCI: Journal of the National Cancer Institute* 2010; Volume 102, Issue 20:1557–1567,.

*7.* Karimi Zarchi, Mojgan et al. Diagnostic Value of the CareTM HPV Test in Screening for Cervical Intraepithelial Neoplasia Grade 2 or Worse.*Asian Pacific journal of cancer prevention : APJCP* 2017;18 :3 687-693.

8. Arbyn M, Smith SB, Temin S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018; 363:k4823.

9. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al . Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. The Lancet 2011; 378; 1868-73

10. Katanga J, Kjaer SK, Manongi R, Wu CS, Iftner T, Waldstrom M et al. Performance of careHPV, hybrid capture 2 and visual inspection with acetic acid for detection of high-grade cervical lesion in Tanzania: A cross-sectional study. PLoS One. 2019;14(6):e0218559.

11. Indian Council of Medical Research, National Cancer Registry programme: Three Year Report of Population based Cancer Registries 2012-2014 (Report of 27 PBCRs in India). 2016https://www.ncdirindia.org/All_Reports/PBCR_REPORT_2012_2014

12. Profile of Cancer and Related Health Indicators in the North East Region of India. ICMR-National Centre for Disease Informatics and Research, Bengaluru, 2021

https://ncdirindia.org/All_Reports/NorthEast2021/resources/NE_Complete.pdfAccessed     24 April 2021

13. BaenaA ,Vuyst H.D, MesherDet al. Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer Epidemiol Biomarkers Prev 2020 ; 29:2261-2268

14. Duttagupta C, Sengupta S, Roy M et al.Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India. Int J Gynecol Cancer 2004 ;14: 293 – 303.

15.  Senapati1  R, Nayak B, Kar S K et al. HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India. BMC Infectious Diseases 2017 ; 17:30.

16.  Kapoor C S , Sharma M .Prevalence of HPV infection in reproductive aged female in Delhi NCR region.Clinical Epidemiology and Global Health 2020 ; 8:612–615.

17. Dey S, Pahwa P, Arti Mishra et al. Reproductive Tract infections and Premalignant Lesions of Cervix: Evidence from Women Presenting at the Cancer Detection Centre of the Indian Cancer Society, Delhi, 2000-2012.  J ObstetGynaecolIndia 2016 ; 66(Suppl 1):441-51.

18. Mulay K, Swain M, Patra S et al. A comparative study of cervical smears in an urban Hospital in India and a population-based screening program in Mauritius. Indian J Pathol Microbiol 2009 ; 52:34–37.

19. Discacciati MG, Barboza BM, Zeferino LC . Why does the prevalence of cytopathological results of cervical cancer screening can vary significantly between two regions of Brazil? Rev Bras Ginecol Obstet 2014 ; 36:192–197.

20. Zhao XL ,Xu XQ , Duan XZ et al. Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: A population-based study in rural China. Int J Cancer 2020 ; 147:1275-1285.

21.Kjellberg L, Hallmans G, Ahren A M et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br. J. Cancer 2000; 8: 1332-1338.

22. Oh HY, Seo SS, Kim MK et al. Synergistic effect of viral load and alcohol consumption on the risk of persistent high-risk human papillomavirus infection. PLoS ONE 2014 ; 9:522.

 23. Min KJ, Lee JK, Lee S et al. Alcohol consumption and viral load are synergistically associated with CIN1. PLoS ONE 2013 ; 8:522.

24.  Friedenreich C.M., Speidel T.P., Neilson H.K., Langley A.R., Courneya K.S., Magliocco A.M., Cook L.S. Case-control study of lifetime alcohol consumption and endometrial cancer risk. Cancer Cause Control 2013; 24:1995–2003.

25. Zhou Y, Zheng J, Li S et al. Alcoholic Beverage Consumption and Chronic Diseases. Int J Environ Res Public Health 2016; 13:522 .

26. Raychaudhuri S,  Mandal S. Socio-Demographic and Behavioural Risk Factors for Cervical Cancer and Knowledge, Attitude and Practice in Rural and Urban Areas of North Bengal, India , Asian Pacific J Cancer Prev 2012 ;13: 1093-1096.

27. P. Appleby, V. Beral, B. A. de Gonzalez, and D. Colin. Cervical ´cancer prevention and hormonal contraception . Lancet2007 ; vol. 370, no. 9599, pp. 1591–1592.

28. Yu Q,  Liu Q, Gao Y et al. Human papillomavirus type 18/16 infection and prevalence among middle-aged and older Chinese rural women: a cross-sectional survey in Wufeng, Hubei Province. Women & Health 2019; 59:1105-1117.

29. Munoz N, Franceschi S, Bosetti C et al. Multicentric Cervical Cancer Study G Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study. Lancet 2002 ; 359:1093–1101.

30.  Adsul P,  Srinivas V ,  Gowda S et al. A community-based, cross-sectional study of hrHPV DNA self-sampling-based cervical cancer screening in rural Karnataka, India. Int J GynecolObstet  2019; 146: 170–176.

**Table I: Socio demographic, behavioural characteristics of women and risk factor associated with hr-HPV infection**

| Variables | | HPV | | O.R | 95%CI | P- Value |
|---|---|---|---|---|---|---|
| | | Negative | positive | | | |
| **Education** | Graduate<br>Primary<br>High<br>Illiterate | 56<br>39<br>244<br>141 | 2<br>2<br>7<br>5 | Ref<br>1.436<br>0.80233<br>0.9929 | 0.1938 to 10.64<br>0.1624 to 3.973<br>0.1871 to 5.270 | 0.7219<br>0.7878<br>0.9933 |
| **Tobacco** | NO<br><br>YES | 299<br><br>165 | 4<br><br>12 | Ref<br><br>5.436 | 1.726-17.125 | 0.001# |
| **Betel nut** | NO<br><br>YES | 137<br><br>327 | 4<br><br>12 | Ref<br>1.25 | 0.398-3.966 | 0.696 |
| **Alcohol** | NO<br><br>YES | 372<br><br>92 | 2<br><br>14 | Ref<br><br>28.3 | 6.321-126.733 | <0.0001# |
| **Use of contraceptives** | NO<br><br>YES | 322<br><br>144 | 12<br><br>4 | 1.342<br><br>Ref | 0.4253 to 4.232 | 0.6148 |
| **Menstrual_Cycle** | Regular<br><br>Irregular | 408<br><br>56 | 13<br><br>3 | Ref<br><br>1.68 | 0.465-6.084 | 0.424 |
| **Sanitary Pad** | YES<br>NO | 324<br>143 | 6<br>10 | Ref<br>3.776 | 1.346 to 10.59 | 0.0070# |
| **Urinary tract infection** | YES<br><br>NO | 153<br><br>311 | 9<br><br>7 | 2.613<br><br>Ref | 0.955-7.150 | 0.053 |
| **Urinary tract infection of Husband** | YES<br><br>NO | 11<br><br>453 | 1<br><br>15 | 2.745<br><br>Ref | 0.333-22.662 | 0.328 |
| **Age of marriage** | ≤18<br>19-30 | 174<br>268 | 6<br>9 | 0.6552<br>0.6381 | 0.07482 to 5.737<br>0.07672 | 0.5274<br>0.6750 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | >30 | 19 | 1 | Ref | to 5.307 | |
| **Age of first pregnancy** | ≤18<br>19-24<br>25-30<br>>30<br>NIL | 103<br>195<br>110<br>34<br>23 | 5<br>6<br>3<br>1<br>0 | Ref<br>0.6338<br>0.5618<br>0.6059<br>---- | 0.1888 to 2.127<br>0.1309 to 2.411<br>0.06833 to 5.372<br>--- | 0.4569<br>0.4321<br>0.6494<br>--- |
| **Number of children** | Nill<br>1-2<br>≥3 | 24<br>296<br>160 | 0<br>5<br>10 | ---<br>0.2703<br>Ref | ---<br>0.09079 to 0.8046 | ---<br>0.0122# |

**# Statistically Significant**

**Table II**: hr-HPV DNA positivity (careHPV) and Positive PAP smear

| Result | No. of Participants (%) |
|---|---|
| Care HPV DNA Positivity | 16 (**3.3%**) |
| ASCUS | 13 (**2.7** %) |
| LSIL | 18 (**3.75%**) |
| HSIL | 03 ( **0.62%**) |

**Table III: Socio demographic , behavioral characteristics of women and risk factor associated with PAP outcome**

| Variables | | PAP | | O.R | 95%CI | P- Value |
|---|---|---|---|---|---|---|
| | | Negative | positive | | | |
| **Education** | Graduate | 56 | 2 | Ref | 0.1938 to 10.64 | 0.7219 |
| | Primary school | 39 | 2 | 1.436 | 0.1624 to 3.973 | 0.7878 |
| | High school | 244 | 7 | 0.80233 | 0.1871 to 5.270 | 0.9933 |
| | Illiterate | 141 | 5 | 0.9929 | | |
| **Tobacco** | NO | 290 | 16 | Ref | 1.261 to 4.908 | 0.007# |
| | YES | 153 | 21 | 2.488 | | |
| **Betel nut** | NO | 147 | 11 | Ref | 0.5643 to 2.442 | 0.668 |
| | YES | 296 | 37 | 1.174 | | |
| **Alcohol** | NO | 349 | 24 | Ref | 0.9862 to 4.101 | 0.051 |
| | YES | 94 | 13 | 2.011 | | |
| **Use of contraceptives** | NO | 302 | 11 | 1.104 | 0.5303 to 2.297 | 0.792 |
| | YES | 141 | 26 | Ref | | |
| **Menstrual_Cycle** | Regular | 348 | 7 | Ref | 6.111 to 33.59 | <0.001# |
| | Irregular | 132 | 30 | 14.33 | | |

| | | | | Ref | 3.601 to | |
|---|---|---|---|---|---|---|
| **Sanitary Pad** | YES | 358 | 12 | | 15.33 | P<0.0001# |
| | NO | 122 | 25 | 7.431 | | |
| **Urinary tract infection of spouse** | YES | 175 | 25 | 4.069 | 1.989 to 8.328 | <0.001# |
| | NO | 305 | 12 | Ref | | |

**# Statistically Significant**

**Table IV: Validation of care HPV samples by Hybrid capture**

| Sample | RLU | RLU/CO |
|---|---|---|
| S1 | 3935 | 1.72 |
| S2 | 10253 | 4.50 |
| S3 | 8325 | 3.65 |
| S4 | 3433 | 1.50 |
| S5 | 22073 | 9.70 |
| S6 | 10253 | 4.50 |
| S7 | 252933 | 111.17 |
| S8 | 238072 | 104.64 |
| S9 | 211069 | 92.77 |
| S10 | 372243 | 163.62 |
| S11 | 21517 | 9.45 |
| S12 | 49053 | 21.56 |
| S13 | 10885 | 4.78 |
| S14 | 302005 | 132.74 |
| S15 | 3974 | 1.74 |
| S16 | 4749 | 2.08 |

A.

B.

**Figure1**: Cervical cytological findings as determined by the PAP stain using OG-6 and EA-50 **A:** Low-Grade Squamous Intra-epithelial Lesion (LSIL); B. High-Grade Squamous Intra-epithelial Lesion (HSIL)